On January 21, 2025, David Mott, a Director at Ardelyx Inc, purchased 199,000 shares of the company, as reported in the SEC Filing. Following this transaction, the insider now holds a total of 1,937,765 shares in Ardelyx Inc. Ardelyx Inc (ARDX, Financial) is a biopharmaceutical company focused on developing innovative therapies for unmet medical needs. The company's primary focus is on gastrointestinal and cardiorenal diseases. The insider's recent purchase is part of a broader trend, as over the past year, David Mott has acquired a total of 628,168 shares and has not sold any shares. In contrast, the overall insider transaction history for Ardelyx Inc shows 3 insider buys and 63 insider sells over the same period.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
